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Abstract
In the intrinsic pathway of apoptosis, cell-damaging signals promote the release of cytochrome c
from mitochondria, triggering activation of the Apaf-1 and caspase-9 apoptosome. The ubiquitin
E3 ligase MDM2 decreases the stability of the proapoptotic factor p53. We show that it also
coordinated apoptotic events in a p53-independent manner by ubiquitylating the apoptosome
activator CAS and the ubiquitin E3 ligase HUWE1. HUWE1 ubiquitylates the antiapoptotic factor
Mcl-1, and we found that HUWE1 also ubiquitylated PP5 (protein phosphatase 5), which
indirectly inhibited apoptosome activation. Breast cancers that are positive for the tyrosine
receptor kinase HER2 (human epidermal growth factor receptor 2) tend to be highly aggressive. In
HER2-positive breast cancer cells treated with the HER2 tyrosine kinase inhibitor lapatinib,
MDM2 was degraded and HUWE1 was stabilized. In contrast, in breast cancer cells that acquired
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resistance to lapatinib, the abundance of MDM2 was not decreased and HUWE1 was degraded,
which inhibited apoptosis, regardless of p53 status. MDM2 inhibition overcame lapatinib
resistance in cells with either wild-type or mutant p53 and in xenograft models. These findings
demonstrate broader, p53-independent roles for MDM2 and HUWE1 in apoptosis and specifically
suggest the potential for therapy directed against MDM2 to overcome lapatinib resistance.
INTRODUCTION
Mutation of the tumor suppressor p53 in ~50% of human tumors promotes both unrestrained
cell proliferation and a failure of cells to die appropriately by apoptosis (1, 2). MDM2 is a
key p53 inhibitor and prevents transcription of p53 target genes and induces p53
polyubiquitylation and degradation (3-7). In this regard, MDM2 has been viewed as an
indirect, p53-dependent apoptotic regulator.
In a subset of cancers, tumorigenesis is driven by aberrantly activated tyrosine kinases that
promote prosurvival and antiapoptotic signaling (8-10). In these tumors, targeted kinase
inhibition triggers apoptosis and tumor regression. However, development of acquired
therapeutic resistance has limited the clinical efficacy of this important class of targeted
cancer drugs. Therapeutic resistance can result from mutations in the tyrosine kinase itself
(for example, imatinib-resistance stemming from mutation of Bcr-Abl in chronic myeloid
leukemias), but this is not always the case (11, 12). Under these circumstances, dissection of
signal transduction pathways in resistant cells may reveal novel interactions among
signaling molecules.
Overexpression or amplification of the HER2 (human epidermal growth factor receptor 2)
receptor tyrosine kinase in 20 to 30% of breast cancers is associated with poor clinical
outcomes (13). Several HER2-targeted therapeutics have been approved or are in clinical
trials, including trastuzumab (trade name Herceptin), a monoclonal antibody directed against
the extracellular domain of HER2, and lapatinib (trade name Tykerb), a small molecule that
reversibly inhibits the kinase activities of HER2 and EGFR (epidermal growth factor
receptor) (14, 15). Conventionally, a breast cancer patient undergoes lapatinib treatment
after the development of therapeutic resistance to trastuzumab. However, the antitumor
effects of lapatinib monotherapy are generally short-lived, with cancer cells inevitably
developing resistance to this drug over time (16).
Because mutations in HER2 itself are not typically seen in acquired lapatinib resistance,
alternative mechanisms underlying acquired lapatinib resistance have been evaluated (15,
17-22). Several studies have identified apoptotic inhibitors that show increased abundance in
lapatinib-resistant cells, including X-linked inhibitor of apoptosis protein (XIAP) (18) and
Mcl-1, an antiapoptotic Bcl-2 family member [seen in lapatinib-resistant colon cancer cells
(19)]. It has been recently demonstrated that the simultaneous inhibition of the Bcl-2 family
proteins Bcl-2, Bcl-xL, and Mcl-1 can synergize with lapatinib (23). Nevertheless, the
molecular basis of acquired resistance remains to be fully elucidated.
In seeking to understand the molecular basis of lapatinib resistance, we undertook a
systematic comparison of apoptotic signaling pathways in isotype-matched lapatinib-
sensitive and lapatinib-resistant HER2+ breast cancer cells. We identified multiple
antiapoptotic alterations both upstream and downstream of mitochondria in resistant cells.
These studies revealed an unexpected signaling network in which the ubiquitin E3 ligase
MDM2 ubiquitylated another E3 ligase, HUWE1, thereby increasing the abundance of its
substrates, Mcl-1 and protein phosphatase 5 (PP5), an indirect inhibitor of the apoptosome.
Thus, HUWE1 transmits a signal from MDM2 to control apoptotic events both upstream
and downstream of mitochondria. These MDM2-dependent pathways were subverted in
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lapatinib-resistant cells, and regardless of cellular p53 status, inhibition of MDM2 rectified
apoptotic defects, thereby overcoming drug resistance.
RESULTS
Mcl-1 stabilization in lapatinib-resistant breast cancer cells
To analyze the molecular mechanisms underlying lapatinib resistance, we derived four
independent lapatinib-resistant HER2-positive breast cancer cell lines by continuous culture
of BT474, SKBR3, SUM190, and AU565 cells in the presence of clinically relevant
concentrations of lapatinib (20). Regardless of estrogen receptor, progesterone receptor, or
p53 status (fig. S1 and table S1), all four parental sensitive cell lines died from apoptosis in
response to lapatinib, whereas all four resistant lines (hereinafter referred to as rBT474,
rSKBR3, rSUM190, and rAU565) did not (Fig. 1A and fig. S2). As previously reported
(20), lapatinib inhibited the tyrosine autophosphorylation of HER2 even in resistant cells
(Fig. 1B). Furthermore, phosphorylation of both Akt and extracellular signal-regulated
kinase 1/2 (ERK1/2), two primary downstream effectors in HER2-positive breast cancer,
was also attenuated in sensitive and resistant cells treated with lapatinib (Fig. 1, C and D).
Note that we did not detect a consistent increase in the kinase activity of SRC (fig. S3),
which has been implicated in acquired resistance to trastuzumab or lapatinib in HER2-
positive breast cancer (21, 24), nor did the SRC inhibitor dasatinib affect MDM2 protein
abundance or apoptotic resistance in lapatinib-resistant cells (fig. S4).
Because lapatinib promotes tumor regression, at least in part, by inducing apoptosis, we
speculated that apoptotic signaling might be altered in resistant cells. Indeed, lapatinib
induced mitochondrial cytochrome c release in parental BT474 cells, but not rBT474 cells
(fig. S5), suggesting that pro- and antiapoptotic Bcl-2 family proteins that govern the
mitochondrial outer membrane permeability might be modulated in the lapatinib-treated
resistant cells. Although there did not appear to be substantial differences in the abundance
of the Bcl-2 family member Bim (Fig. 1E) between sensitive and resistant cells, as reported
for colon cancer cells (19), the abundance of the antiapoptotic Bcl-2 member Mcl-1 was
increased in the resistant breast cancer cells treated with lapatinib (Fig. 1E and fig. S6); in
the sensitive cells, Mcl-1 abundance decreased upon treatment with lapatinib, whereas
Mcl-1 abundance increased in the resistant cells maintained in the presence of lapatinib (Fig.
1E and fig. S6).
35S-labeled Mcl-1 was rapidly degraded in cell-free lysates prepared from sensitive cells,
but was markedly delayed in those prepared from resistant cells, indicating that the observed
differences in Mcl-1 abundance stemmed from differences in Mcl-1 stability (Fig. 1F and
fig. S7). Although the Mcl-1 protein half-life was prolonged in resistant cell lysates, this was
particularly prominent in lysates from cells treated with lapatinib (for example, lapatinib-
treated rBT474 cells) (Fig. 1G). Addition of the deubiquitylase inhibitor ubiquitin aldehyde
to the lysates did not prevent the failure to degrade 35S-labeled Mcl-1 in resistant cells (fig.
S8), suggesting that Mcl-1 stabilization might be secondary to a defect in Mcl-1
ubiquitylation, rather than enhanced deubiquitylation. To examine Mcl-1 ubiquitylation
directly, we co-transfected FLAG-tagged Mcl-1 together with hemagglutinin (HA)-tagged
ubiquitin and examined the ubiquitylation of immunoprecipitated Mcl-1. In the absence of
lapatinib, Mcl-1 protein was equally ubiquitylated in SKBR3 and rSKBR3 cells (Fig. 1H).
Lapatinib treatment enhanced Mcl-1 ubiquitylation in SKBR3 cells but diminished Mcl-1
ubiquitylation in rSKBR3 cells (Fig. 1H), suggesting that the increased abundance of Mcl-1
protein in the lapatinib-resistant cells might result from a lapatinib-dependent defect in the
Mcl-1 ubiquitylation machinery.
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Incorrect apoptosome assembly in lapatinib-resistant cells
In analyzing the mechanism of lapatinib resistance, we noted that the resistant cells failed to
activate caspases when purified cytochrome c was added directly to lysates, whereas
cytochrome c induced robust caspase activation in parental cells, although the abundance of
Apaf-1, caspase-9, and caspase-3 was similar in resistant and sensitive cells (Fig. 2A and
fig. S9). As we observed for Mcl-1 protein stability, the failure of cytochrome c to induce
caspase activation in lapatinib-resistant cells was lapatinib-dependent. Caspase activation
did not occur in lysates from resistant cells cultured in the presence of lapatinib, a defect that
was rescued by removing lapatinib from the culture medium (Fig. 2, A and B).
PP5 stabilization in lapatinib-resistant breast cancer cells
Recruitment of caspase-9 to the apoptosome is blocked by HSP90β binding to the CARD
(caspase recruitment domain) domain of Apaf-1. In leukemia cells, decreased
phosphorylation of HSP90β at residues Ser226 and Ser255 leads to a stronger interaction
between Apaf-1 and HSP90β (25). Phosphorylation of HSP90β at both Ser226 and Ser255
was also markedly decreased in lapatinib-treated resistant cells compared to sensitive cells
(Fig. 2, C, D, and E).
Because lapatinib did not prevent the phosphorylation of HSP90β in parental BT474 cells
(Fig. 2C), lapatinib was unlikely to inhibit an HSP90β-directed kinase [such as casein kinase
2 (CK2) (26) (fig. S10)], suggesting that an HSP90β-directed phosphatase might be
modulated in response to lapatinib. PP5 has been reported to control the phosphorylation
status of HSP90 (27). Therefore, we hypothesized that the decreased phosphorylation of
HSP90β in lapatinib-resistant cells might result from increased PP5 activity. Indeed,
lapatinib treatment triggered a gradual decrease in PP5 abundance in sensitive parental cells,
but not in resistant cells (Fig. 2F and fig. S11). Moreover, the protein half-life of PP5 was
longer in resistant than in the parental cells (Fig. 2G). Accordingly, the ubiquitylation of PP5
was greater in sensitive than in resistant cells (Fig. 2H).
The role of the ubiquitin E3 ligase HUWE1 in the degradation of both Mcl-1 and PP5
PP5 stabilization could result from a defect in an E3 ligase activity responsible for PP5
ubiquitylation in lapatinib-resistant cells. Hence, we sought to identify a PP5-directed E3
ligase through chromatographic purification. Cytosolic lysates prepared from SKBR3 cells
were fractionated on a Q Sepharose column, and ubiquitylation of 35S-labeled PP5 by each
fraction [supplemented with E1, E2, ATP (adenosine 5′-triphosphate), and ubiquitin] was
analyzed by SDS-polyacrylamide gel electrophoresis. Most of the PP5-ubiquitylating
activities were eluted with 500 mM NaCl (fig. S12). Because Mcl-1 stability changed in
response to lapatinib, we speculated that an Mcl-1-directed E3 ubiquitin ligase might also
regulate PP5 stability. Indeed, immunoblotting of Q Sepharose fractions revealed that
HUWE1 (also known as Mule, ARF-BP1, and HectH9), a HECT domain E3 ligase that
targets Mcl-1 for degradation (28), was also eluted with 500 mM NaCl, corresponding to the
fraction with PP5-ubiquitylating activity (fig. S12).
In agreement with these observations, we found that HA-HUWE1 co-immunoprecipitated
with endogenous PP5 (Fig. 3A). Moreover, knockdown of HUWE1 by small interfering
RNA (siRNA) increased the abundance of both PP5 and Mcl-1 in BT474 cells (Fig. 3B).
Conversely, overexpression of HA-HUWE1, but not catalytically inactive HA-HUWE1(C/
S), reduced PP5 and Mcl-1 protein abundance (Fig. 3C and fig. S13). In the presence of both
E1 and E2, wild-type recombinant HUWE1 protein, but not HUWE1(C/S), ubiquitylated
recombinant PP5 in vitro (Fig. 3D). In BT474 cells, binding of PP5 to HUWE1 markedly
increased after lapatinib treatment (Fig. 3E). In contrast, association of PP5 with HUWE1
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was undetectable in rBT474 cells regardless of lapatinib treatment (Fig. 3E). Together, these
results suggested that HUWE1 is a bona fide E3 ligase for PP5.
Decreased abundance of CAS in lapatinib-resistant cells
Decreased phosphorylation of HSP90β downstream of PP5 stabilization might explain
apoptosome inhibition in the lapatinib-treated resistant cells, but when we resolved cell
lysates by gel filtration, we saw not only a failure to recruit caspase-9 to Apaf-1 (which
could be explained if HSP90β blocked caspase-9 recruitment) but also a failure of the
majority of Apaf-1 to oligomerize (Fig. 3F). Moreover, upon addition of cytochrome c to
resistant cell lysates, we detected a small fraction of Apaf-1 and caspase-9 in large (1000 to
1400 kD) fractions (Fig. 3F, shown by asterisks), which has been previously described as
incorrectly assembled inactive complexes (29).
Without nucleotide exchange, cytochrome c induces Apaf-1 to form non-functional
aggregates (29). Accordingly, we examined the abundance of PHAP1, HSP70, and CAS
(also known as CSE1L or Exportin-2), essential components of the nucleotide exchange
factor required for loading Apaf-1 with dATP (29). We found that CAS protein abundance
was decreased in resistant cells compared with parental cells, most notably in the presence
of lapatinib (Fig. 4A and fig. S14). CAS protein abundance declined over time after the
addition of lapatinib to resistant cells, but lapatinib removal restored the abundance of CAS
to levels comparable to the parental cells (Fig. 4, A and B). Treatment of parental cells with
lapatinib did not affect CAS protein abundance (Fig. 4A). CAS protein was stabilized in
sensitive cells, but destabilized in lapatinib-treated resistant cells (Fig. 4C). Accordingly,
ubiquitylation of CAS was nearly undetectable in sensitive cells even in the presence of
MG132, whereas ubiquitylated species of CAS were readily detected in resistant cells and
more prominent in the presence of lapatinib (Fig. 4D and fig. S15). These data suggest that
decreased CAS abundance in lapatinib-resistant cells results from augmented CAS protein
ubiquitylation.
To determine the mode of CAS degradation, we analyzed the CAS protein sequence and
identified a potential binding motif for the RING finger ubiquitin ligase MDM2 (30, 31)
(fig. S16). CAS interacts with p53 (32); however, MDM2 coimmunoprecipitated with CAS
in BT474 and p53-null H1299 cells (Fig. 4, E and F). When Trp127, a conserved residue in
the MDM2 binding motif, was replaced with Ala, binding of CAS to MDM2 was
diminished (Fig. 4E). Moreover, when expressed in H1299 cells lacking p53, ubiquitylation
of CASW127Awas suppressed compared with that of wild-type CAS (Fig. 4G). Furthermore,
transient overexpression of MDM2 decreased the abundance of wild-type CAS, but not that
of the F123A mutant in which the conserved Phe123 in the MDM2 binding motif was
replaced with Ala (Fig. 4H). Together, these results indicate that CAS is an MDM2 target. In
BT474 cells, the CAS-MDM2 interaction decreased in the presence of lapatinib, whereas
binding was enhanced in rBT474 cells under the same conditions (Fig. 4F), consistent with
the idea that augmented ubiquitylation and subsequent degradation of CAS protein in
lapatinib-resistant cells are mediated by MDM2.
Identification of MDM2 as a HUWE1-directed E3 ligase
High HUWE1 and low MDM2 activities in sensitive cells resulted in reduced abundance of
Mcl-1 and PP5 and sustained abundance of CAS, respectively, rendering the sensitive cells
prone to apoptosis. In parental cells, HUWE1 protein abundance remained stable in the
presence of lapatinib, whereas MDM2 rapidly decreased (Fig. 5A and fig. S17). Conversely,
when resistant cells were treated with lapatinib, HUWE1 abundance decreased, whereas
MDM2 abundance was maintained (Fig. 5A and fig. S17). Reduction of HUWE1 in resistant
cells appeared to be due to lapatinib-induced protein degradation. In the absence of
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lapatinib, HUWE1 was stable in both BT474 and rBT474 cells. However, in lapatinib-
treated rBT474 cells, HUWE1 protein half-life became considerably shorter, compared to
that in BT474 cells (Fig. 5B). Although both HUWE1 and MDM2 are p53-targeting E3
ligases (5-7, 33) (and MDM2 abundance can also be modulated in a feedback loop by p53-
induced transcription), mutant p53 is present in three of the four cell lines (BT474, SKBR3,
and SUM190) (table S1 and fig. S1), suggesting that the observed changes in HUWE1 and
MDM2 protein abundance are independent of the transcriptional activity of p53.
Through protein sequence analysis, we determined that HUWE1 contained a putative
MDM2 binding motif at residues 1198 to 1205 (fig. S18); the interaction of these two E3
ligases was confirmed by immunoprecipitation of endogenous proteins (fig. S19). The N-
terminal portion of the HUWE1 protein (amino acids 1 to 2474) as well as the full-length
protein interacted with MDM2 (Fig. 3A). Moreover, replacement of the conserved Trp1202
with Ala (HUWE1W1202A) reduced binding between the two proteins (Fig. 5C). The
HUWE1-MDM2 interaction was evident not only in BT474 cells but also in H1299 cells,
again indicating that their binding is neither specific for breast cancer cells nor mediated by
p53 (Figs. 3A and 5C and fig. S19). To examine the binding affinity between HUWE1 and
MDM2, we performed fluorescence polarization-based competitive binding assays using
recombinant MDM2 protein and modified p53 peptide labeled with FAM as a fluorescent
probe (34). The HUWE1 peptide competitively inhibited binding of the fluorescent probe to
MDM2 with a Ki (inhibition constant) value of 1.5 μM and was a threefold more potent
inhibitor of probe binding than the p53 peptide (amino acids 13 to 29, which constitutes the
MDM2 binding motif) (Fig. 5D).
To determine whether MDM2 is a HUWE1-directed E3 ligase, we overexpressed MDM2 in
H1299 cells. MDM2 expression reduced HUWE1 protein abundance in a dose-dependent
manner (Fig. 5E). In contrast, siRNA knockdown of MDM2 increased HUWE1 protein
abundance (Fig. 5F). Using a truncated mutant of HUWE1 (HUWE11–2474) to allow
visualization of an electrophoretic mobility shift, we confirmed that, in the presence of both
E1 and E2, MDM2 could ubiquitylate HUWE1 in vitro (Fig. 5G). Last, we demonstrated
that lapatinib treatment triggered degradation of HUWE1 in resistant cells transfected with
control siRNA, but when these cells were transfected with MDM2 siRNA, HUWE1 stability
was markedly increased, even in the presence of lapatinib (Fig. 5H). Together, these results
are consistent with MDM2 acting as a HUWE1-directed ligase.
Reversal of lapatinib resistance by inhibition of MDM2
Our findings raised the interesting possibility that the changes in Mcl-1, PP5, and CAS in
lapatinib-resistant cells could all be traced to high MDM2 activity in the resistant cells.
Accordingly, when resistant cells were co-treated with lapatinib, MDM2 knockdown
induced significant apoptotic cell death (Fig. 6A). To evaluate this further, we implanted
xenografts of rBT474 cells stably expressing control or MDM2 short hairpin RNAs
(shRNAs) into the mammary fat pads of female nude mice (Fig. 6B). Without lapatinib
treatment, tumors developed similarly for all tumors. Oral lapatinib administration induced
regression of xenografted tumors expressing MDM2 shRNAs, whereas control tumors
continued to grow (Fig. 6B). Moreover, by the end of the treatment period, 6 of 10 mice in
the MDM2 knockdown group had tumors smaller than 50 mm3.
A hydrophobic pocket in the N terminus of MDM2 binds to the trans-activation domain of
p53 (30). If MDM2 bound HUWE1 in the same fashion as suggested by the fluorescence
polarization-based assays (Fig. 5D), the MDM2 antagonist Nutlin-3a, which disrupts the
p53-MDM2 complex, might also be expected to interfere with HUWE1-MDM2 binding
(35). To exclude the possibility that any effects of Nutlin-3a might be mediated by the p53-
MDM2 interaction, we used p53-null H1299 cells. Catalytically inactive HUWE1
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[HUWE1(C/S)] bound to endogenous MDM2, and this interaction was reduced by Nutlin-3a
(Fig. 6C). Moreover, Nutlin-3a also prevented lapatinib-induced degradation of HUWE1
(Fig. 6D and fig. S20), suggesting that Nutlin-3a stabilizes HUWE1 by disrupting HUWE1-
MDM2 binding. Consequently, Nutlin-3a also suppressed lapatinib-induced up-regulation of
Mcl-1 and PP5 (Fig. 6D and fig. S20). CAS degradation was also inhibited by Nutlin-3a
(Fig. 6D and fig. S20).
To examine the effect of Nutlin-3a in vivo, mice bearing BT474 or rBT474 xenografts were
randomly assigned to vehicle, lapatinib, Nutlin-3 (a racemic mixture of the enantiomers
Nutlin-3a and Nutlin-3b), or lapatinib and Nutlin-3. Lapatinib alone or a combination of
lapatinib and Nutlin-3 significantly suppressed growth of BT474-derived tumors, whereas
Nutlin-3 alone only modestly inhibited tumor growth (Fig. 6E). Neither lapatinib nor
Nutlin-3 inhibited rBT474-derived tumor growth as a single agent (Fig. 6E). However,
combination treatment of lapatinib and Nutlin-3 significantly suppressed tumor growth,
resulting in ~50% reduction in tumor volume (Fig. 6E). These experiments were repeated
using p53-positive AU565 and rAU565 cells. Lapatinib substantially inhibited the growth of
tumors derived from AU565 cells, but not those derived from rAU565 cells (fig. S21).
Nutlin-3 treatment alone moderately inhibited the growth of tumors derived from these p53-
positive cells, but combined lapatinib and Nutlin-3 treatment reduced tumor volume by
~50% by the end of the evaluation period (fig. S21). Tissue culture experiments conducted
in parallel with all four sensitive and resistant cell line pairs using the MDM2 antagonist
MI-219 (34) suggest that similar effects are likely to be obtained with other MDM2
inhibitors (fig. S2). Moreover, the ability of the MDM2 inhibitors to resensitize resistant
cells to lapatinib was not compromised by RNA interference (RNAi)-mediated knockdown
of p53 in rAU565 cells (Fig. 6F). Together, these results demonstrate that regardless of p53
status, an MDM2 inhibitor such as Nutlin-3a or MI-219 can reverse lapatinib resistance,
potentially by stabilizing CAS and HUWE1, thereby promoting loss of PP5 and Mcl-1 (Fig.
6G).
DISCUSSION
Here, we have demonstrated that multiple changes in the abundance of apoptotic regulators,
both upstream and downstream of mitochondrial cytochrome c release, cause resistance to
lapatinib. Furthermore, these changes could be attributed to a previously unsuspected
network of MDM2 (and HUWE1) substrates that does not include p53. Failure to degrade
MDM2 in response to lapatinib in all four independently derived lapatinib-resistant cell lines
was the key factor in increasing the abundance of components of the antiapoptotic
machinery in these cells (Fig. 6G).
We identified changes in mitochondrial cytochrome c release after lapatinib treatment, but
we have also found that the apoptosome is refractory to cytochrome c–induced activation in
the resistant cells. There is some debate as to the importance of apoptosome inhibition in
cancers that already have a block to mitochondrial cytochrome c release. However, we
postulate that the block is more profound when several loci in the apoptotic pathway are
affected: Even if small amounts of cytochrome c were released in response to lapatinib in
the resistant cells, efficient caspase activation would be inhibited at the level of the
apoptosome. Because the abundance of both PP5 and Mcl-1 is controlled by HUWE1,
apoptotic inhibition both upstream and downstream of the mitochondria could be controlled
coordinately.
We also determined that the abundance of CAS was decreased through MDM2-mediated
ubiquitylation. Knockdown of CAS renders breast cancer cells resistant to apoptosis (36).
CAS also binds to a subset of p53 target genes to regulate p53-mediated gene expression
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(32). In this regard, our results raise the interesting possibility that, in addition to
ubiquitylation of p53, MDM2 might also modulate the p53 signaling pathway by targeting
CAS for degradation.
Notably, high MDM2 activity promotes not only degradation of CAS protein but also a
decrease in HUWE1 abundance (and thus increased stability of its substrates). Although
several proteins have been identified as substrates of HUWE1, such as Cdc6, p53, and N-
Myc/c-Myc, little is known about the regulation of this E3 ligase (28, 33, 37-39). It should
be noted that MDM2 substrates in addition to HUWE1 and CAS may also contribute to
lapatinib resistance. For example, MDM2 enhances IRES (internal ribosome entry site)-
mediated translation of XIAP (40). In this regard, it is noteworthy that increased IRES-
mediated XIAP translation has been implicated in inflammatory breast cancer cells with
acquired resistance to lapatinib (18).
The basis for the difference in MDM2 abundance in resistant and sensitive cells is not clear.
This could be secondary to differences in protein stability or in transcription between
resistant and sensitive cells. It is possible that a mutation, modification, or unidentified
binding partner renders MDM2 unable to auto-ubiquitylate, but still able to ubiquitylate
substrates in trans. Alternatively, failure to degrade MDM2 in the resistant cells could result
from a mutation in MDM2 itself, rendering it insensitive to degradative signals triggered by
lapatinib in sensitive cells. Answering these questions will provide a stepping stone from
MDM2 to the relevant signaling factor(s) primarily responsible for the lapatinib resistance
while revealing additional nodes in the MDM2 and HUWE1 regulatory network.
MATERIALS AND METHODS
Cell culture
BT474, SKBR3, and AU565 cells were obtained from the American Type Culture
Collection (ATCC). SUM190 cells were obtained from Asterand Inc. All cell lines were
cultured in RPMI medium containing 10% fetal bovine serum (FBS). Lapatinib-resistant
cells (rBT474, rSKBR3, rAU565, and rSUM190) were established as previously described
(20). Lapatinib-resistant cells were maintained in the presence of 1 μM lapatinib unless
otherwise stated. However, the resistant cells were cultured in lapatinib-free medium for 7
days before the treatment with lapatinib. H1299 cells (from ATCC) were maintained in
Dulbecco’s modified Eagle’s medium with 10% FBS.
Reagents and antibodies
Lapatinib and dasatinib were purchased from LC Laboratories. MG132 and z-VAD were
purchased from Enzo Life Sciences. E1, E2, ubiquitin, and ubiquitin aldehyde were
purchased from Boston Biochem. Nutlin-3a and racemate Nutlin-3 were synthesized and
purified at the Duke Small Molecule Synthesis Facility. Nutlin-3a and Nutlin-3 were also
purchased from Cayman Chemical. Cycloheximide and purified cytochrome c were
purchased from Sigma.
The following antibodies were used: antibodies against HER2, phospho-HER2 (Tyr877),
Akt, phospho-Akt (Thr308), caspase-9, cleaved caspase-3, Bcl2, Bcl-xL, ERK1/2, phospho-
ERK1/2 (Thr202/Tyr204), phospho-SRC (Tyr416), SRC, FLAG, cytochrome c oxidase IV
(Cell Signaling Technology), Apaf-1 (2E12; Enzo Life Sciences), HSP90β (5E12), MDM2
(2A10; Calbiochem), HSP90β (Millipore), phospho-HSP90β (Ser226), phospho-HSP90β
(Ser255), α-tubulin (Abcam), actin, MDM2 (SMP14), HA (F-7) (Santa Cruz Biotechnology),
FLAG M2 (Sigma), Bim, cleaved caspase-3, Mcl-1,PP5,CAS,HSP70(BDTransduction
Laboratories),Mcl-1(BioLegend), HUWE1 (Bethyl Laboratories), and PHAP1 (ProSci).
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Plasmids
HA-HUWE1 constructs in pCMV (porcine cytomegalovirus; wild type, C4341S mutant, and
amino acids 2473 to 4374 mutant) were gifts from K. Helin (University of Copenhagen).
HUWE1 in pENTR was a gift from J. G. Cook (University of North Carolina, Chapel Hill,
NC). HUWE1 in pENTR was recombined with the destination vector pDEST10 (Invitrogen)
for production of His-tagged protein. FLAG-PP5 in pcDNA3 and FLAG-CAS in
p3XFLAG-CMV10 were gifts from X.-F. Wang (Duke University) and C. Prives (Columbia
University), respectively. CAS was also cloned into pENTR and subsequently into
pDEST10 for baculoviral protein expression. PP5 was cloned into pGEX-KG for production
of glutathione S-transferase (GST) fusion protein. Mcl-1 with the N-terminal FLAG tag was
generated from human Mcl-1 (a gift from J. Rathmell, Duke University) and cloned into
pcDNA3. The plasmids encoding GST-MDM2, GST-MDM2C464A, and HA-tagged
ubiquitin were obtained from Addgene (Addgene plasmids 11492, 11493, and 17608) (41,
42). MDM2 was also cloned into pcDNA3 with an N-terminal FLAG tag. All point
mutations (HA-HUWE11-2474, HA-HUWE1W1202A, His-HUWE1C4341S, FLAG-
CASW127A, FLAG-CASF123A) were generated with the QuikChange mutagenesis kit
(Stratagene).
RNA interference
Transient siRNA transfections were performed with Lipofectamine RNAiMAX (Invitrogen)
according to the manufacturer’s instructions. MDM2-specific siRNA (sense: 5′-
CACCUCACAGAUUCCAGCUUCGGAA-3′) and its scrambled siRNA control (sense: 5′-
CACACACUUAGGACCCUUCGU-CGAA-3′) were designed and synthesized by
Invitrogen. siRNA oligos targeting HUWE1 or GFP were previously described (37).
For stable knockdown of MDM2, an shRNA construct in the lentiviral vector pLKO.1-puro
(shMDM2 #1) was purchased from Open Biosystems (sense: 5′-
GATTCCAGAGAGTCATGTGTT-3′). Additional MDM2 shRNA construct (shMDM2 #2;
sense: 5′-TTGAAGTTATTAAAGTCTGTT-3′) and control shRNA construct (sense: 5′-
CTGTGCTGTAGGTGAAACTGT-3′) were also created in the vector pLKO.1-puro
according to Addgene’s pLKO.1 protocol (http://www.addgene.org/plko). Stable
knockdown of p53 was performed with the vector shp53-pLKO.1-puro (Addgene plasmid
19119) (43).
Mouse xenograft experiments
Six-week-old female nude mice were purchased from the National Cancer Institute (NCI)
Frederick National Laboratory. Xenograft tumors were produced by injection into the
mammary fat pad with cells (10 × 106). Tumor volumes were calculated every 3 to 4 days
by caliper measurements of the short (a) and long (b) tumor diameters (volume = a × 2 × b/
2). Lapatinib and Nutlin-3 were formulated in vehicle (water with 0.5% hydroxypropyl
methylcellulose and 0.1% Tween). Mice were dosed orally with vehicle alone, lapatinib
(100 mg/kg), Nutlin-3 (100 mg/kg), or combination of both twice daily by gavage.
Immunoprecipitation
Cells were transiently transfected with the indicated plasmid by FuGene 6 (Roche)
according to the manufacturer’s instructions. Cells were harvested and lysed with
coimmunoprecipitation buffer [10 mM Hepes (pH 7.4), 150 mM KCl, 0.5% NP-40, 1 mM
phenylmethylsulfonyl fluoride, leupeptin (5 μg/ml), and aprotinin (5 μg/ml)]. Cell lysate
was incubated with anti-FLAG M2 agarose (Sigma) or anti-HA affinity matrix (Roche) at
4°C for 2 to 3 hours. The bead pellet was washed three times with coimmunoprecipitation
buffer and then incubated with SDS sample buffer.
Kurokawa et al. Page 9
Sci Signal. Author manuscript; available in PMC 2013 September 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Apoptosis assays
Cell lysates for apoptotic assays were prepared as described previously with buffer A [20
mM Hepes (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride, leupeptin (5 μg/ml), and
aprotinin (5 μg/ml)] (25). Cell lysate (10 μg/μl) was incubated in the presence or absence of
1 mM dATP and various concentrations of cytochrome c at 37°C for 30 min and subjected
to gel filtration, caspase assays, or Western blotting.
Gel filtration was performed as previously described (25). After incubation with cytochrome
c, the cell lysate (in a volume of 250 μl) was loaded onto a Superdex 200 column at a flow
rate of 0.3 ml/min.
Colorimetric caspase assays were performed by incubating cell lysate (3 μl) in 90 μl of
DEVDase buffer [50 mM Hepes (pH 7.5), 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 1
mM EDTA, 10% glycerol] containing the peptide substrate, Ac-DEVD-pNA (200 mM final
concentration; BIOMOL Research Laboratories). Reactions were incubated at 37°C for 30
min. Absorbance of the colorimetric product was measured at 405 nm with a Bio-Rad
microplate reader.
In vitro ubiquitylation assays
Recombinant human PP5 and MDM2 proteins were bacterially expressed with a GST tag.
After purification by glutathione Sepharose 4B (GE Healthcare), the GST tag was cleaved
off by thrombin. Recombinant human wild-type HUWE1, the C4341S mutant (HUWE1 C/
S), and HUWE11-2474 were expressed in the baculovirus system and purified from Sf9 cells.
For in vitro ubiquitylation assays, 100 ng of purified recombinant PP5 or HUWE11-2474 was
incubated with 10 ng of E1, 100 ng of E2 (UbcH5b or UbcH7), 100 μg of ubiquitin, and 0.5
μg of a purified E3 enzyme (HUWE1 wild type, HUWE1 C/S, or MDM2) in 40 μl of
reaction buffer [50 mM tris (pH 7.5), 5 mM MgCl2, 2 mM ATP, 2 mM DTT]. After
incubation at 30°C for 3 hours, the reaction was terminated by the addition of SDS sample
buffer.
Fluorescence polarization binding assays
The binding affinities of HUWE1 and p53 peptides to MDM2 protein were determined by a
quantitative fluorescence polarization-based competitive binding assay, with a recombinant
human His-tagged MDM2 protein (residues 1 to 118) and a FAM-tagged modified p53
peptide as the fluorescent probe (34). The following peptide sequences were tested: p53, Ac-
LSQETFSDLWKLLPENNVL-NH2; HUWE1, Ac-DGTGEFLDAWLMLVEKMVN-NH2.
Statistics
The statistical analysis was carried out with GraphPad Prism software version 4.0c and R
software version 2.15.2. For the densitometric analyses of the immunoblots, significance
was computed with a paired, two-tailed t test on Western blot intensities after normalizing to
the relevant control (CAS, HUWE1, or actin) and after log transforming to correct for
skewness in the distribution.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Mcl-1 is stabilized in lapatinib-resistant cells
(A) Photo micrograph of lapatinib-sensitive and resistant BT474 cells (BT474 and rBT474,
respectively) treated with lapatinib. Scale bars, 400 μm. n = 3 independent experiments. (B)
Cells treated with or without lapatinib in the presence of the caspase inhibitor z-VAD were
immunoblotted with antibodies against phospho-HER2 (p-HER2) (Tyr877) and total HER2.
n = 3 independent experiments. (C) BT474 and rBT474 cells treated with lapatinib and z-
VAD for the indicated times were immunoblotted for phospho-Akt (p-Akt)
(Thr308)andtotalAkt.n=2independentexperiments.(D)BT474 and rBT474 cellstreated with
lapatinib and z-VAD for the indicated times were immunoblotted for phospho-ERK1/2 (p-
ERK1/2) (Thr202 and Tyr204) and total ERK1/2. n = 3 independent experiments. (E) BT474
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and rBT474 treated with lapatinib for the indicated times were immunoblotted for Mcl-1,
Bim, and actin. A representative result is shown (left). Densitometric analysis of the
abundance of Mcl-1 and Bim normalized to that of actin is shown (right). The protein
abundance at the 0 time point in BT474 cells was set at 100%. n = 5 (Mcl-1) and n = 3
(Bim) independent experiments (means ± SEM). (F) 35S-labeled Mcl-1 protein was
incubated in cell-free lysates prepared from BT474 and rBT474. Mcl-1 stability was
monitored by detecting 35S-labeled Mcl-1 at the indicated time points. Representative result
(top panel) and densitometric analysis of the abundance of Mcl-1 (bottom panel) are shown.
The 35S-labeled Mcl-1 abundance at the 0 time point was set at 100%. n = 3 independent
experiments (means ± SEM). (G) 35S-labeled Mcl-1 protein was incubated in lysates
prepared from rBT474 cells treated with or without lapatinib for 7 days. Mcl-1 stability was
monitored by detecting 35S-labeled Mcl-1 at the indicated time points. Representative result
(top) and densitometric analysis of the abundance of Mcl-1 (bottom) are shown. The 35S-
labeled Mcl-1 abundance at the 0 time point was set at 100%. n = 4 independent experiments
(means ± SEM). (H) SKBR3 or rSKBR3 cells expressing FLAG-Mcl-1 and HA-ubiquitin
(Ub) were treated with lapatinib in the presence of z-VAD and harvested after treatment
with MG132 (Z-Leu-Leu-Leu-CHO). FLAG-Mcl-1 immunoprecipitates were
immunoblotted for HA to analyze Mcl-1 ubiquitylation [*nonspecific band, immunoglobulin
G (IgG) heavy chain]. IP, immunoprecipitation; IB, immunoblotting. n = 3 independent
experiments.
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Fig. 2. PP5 stability and post-cytochrome c protection in lapatinib-resistant cells
(A) rBT474 cells were cultured in the presence or absence of lapatinib for 1 week, whereas
BT474 cells were maintained without lapatinib. Cytosolic lysates prepared from BT474 or
rBT474 cells were incubated with 2′-deoxyadenosine 5′-triphosphate (dATP) and various
amounts of cytochrome c (CC). Immunoblotting was performed for caspase-9 (cleaved and
noncleaved) and cleaved caspase-3 (C9 and C3, respectively). n = 5 independent
experiments. (B) Caspase-3 activity was assayed by measuring cleavage of DEVD-pNA
after incubation of the cell lysates with dATP and various concentrations of cytochrome c. A
representative result of five independent experiments is shown. (C) BT474 or rBT474 cells
were cultured in the presence or absence of lapatinib for 6 hours and in the presence of z-
VAD. Recombinant His-tagged HSP90β protein on nickel beads was incubated with the cell
lysates in the presence of [γ-32P]ATP. HSP90β phosphorylation (32P) and total HSP90β
protein [Coomassie brilliant blue (CBB)] are shown. n = 3 independent experiments. (D)
BT474 or rBT474 cells treated with lapatinib for the indicated times were analyzed by
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immunoblotting for phospho-HSP90β (Ser226) and total HSP90β. Densitometric analysis of
phospho-HSP90β (p-HSP90β) normalized to total HSP90β from four independent
experiments is shown (means ± SEM). Phospho-HSP90β at the 0 time point in BT474 cells
was set at 100%. (E) BT474 or rBT474 cells treated with lapatinib were fixed and incubated
with phospho-Hsp90β (Ser255) antibody followed by an Alexa Fluor 488-conjugated
secondary antibody. The phosphorylation status of Ser255 was analyzed by FACS
(fluorescence-activated cell sorting; black: BT474; red: rBT474). n = 2 independent
experiments. (F) BT474 and rBT474 treated with lapatinib for the indicated times were
immunoblotted for PP5 and actin. n = 3 independent experiments. (G) BT474 or rBT474
cells expressing FLAG-PP5 were labeled by the addition of 35[S]Met and 35[S]Cys and
cultured in the presence of lapatinib. 35S radioactivity (35S-labeled PP5) was measured in
FLAG-PP5 immunoprecipitates collected at the indicated time points. Densitometric
analysis of the abundance of 35S-labeled PP5 from five independent experiments is shown
(means ± SEM). The 35S-labeled PP5 abundance at 0 time point was set at 100%. (H)
BT474 or rBT474 cells expressing FLAG-PP5 and HA-Ub were cultured in the presence or
absence of lapatinib and harvested after treatment with MG132. FLAG-PP5
immunoprecipitates were immunoblotted for HA to analyze PP5 ubiquitylation (*IgG heavy
chain). n = 3 independent experiments.
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Fig. 3. HUWE1 is a PP5 ubiquitin ligase
(A) BT474 cells were transfected with empty vector, HA-tagged HUWE1 encoding residues
1 to 2472 (HA-HUWE11-2472), 2473 to 4374 (HA-HUWE12473-4374), or the full-length
protein [HA-HUWE1 WT (wild type)]. HA-HUWE1 immunoprecipitates were
immunoblotted to detect the association of endogenous PP5 and MDM2 (*IgG heavy chain).
After coimmunoprecipitation with HA-HUWE1, PP5 and MDM2 bands showed decreased
mobility (arrows). n = 3 independent experiments. (B) BT474 cells transfected with GFP
(green fluorescent protein)– or HUWE1-specific siRNA were immunoblotted with the
indicated antibodies. A representative result is shown (top). Densitometric analysis of the
abundance of PP5 normalized to that of actin is shown (bottom, n = 7 independent
experiments). The band intensity in GFP siRNA-treated cells was set at 100%. *P < 0.05 by
Student’s t test. (C) BT474 cells transfected with increasing amounts of HA-HUWE1 (WT)
or its catalytically inactive mutant HA-HUWE1 (C/S) along with FLAG-PP5 and GFP
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(transfection control) were immunoblotted for FLAG, HA, GFP, and actin. A representative
result is shown (top). Densitometric analysis of the abundance of FLAG-PP5 normalized to
that of GFP is shown (bottom). The FLAG-PP5 abundance at the lowest amount of HA-
HUWE1 transfected was set at 100%. n = 3 independent experiments. (D) Ubiquitylation of
PP5 was reconstituted in vitro by incubating recombinant PP5 protein with E1, UbcH7 (E2),
ubiquitin (Ub), and recombinant HUWE1 protein [WT or HUWE1 (C/S)] in reaction buffer.
The reactions were immunoblotted for PP5. n = 3 independent experiments. (E) BT474 or
rBT474 cells expressing FLAG-PP5 were treated with lapatinib and harvested after MG132
treatment. FLAG-PP5 immunoprecipitates were immunoblotted to detect the association of
endogenous HUWE1 with PP5. n = 3 independent experiments. (F) Cell lysates prepared
from BT474 or rBT474 cells were incubated with or without dATP and cytochrome c and
subjected to gel filtration on a Superdex 200 column. Each fraction was immunoblotted for
Apaf-1 and caspase-9. The asterisks show that a portion of Apaf-1 in the lapatinib-treated
resistant cell lysate formed higher-order oligomers in response to cytochrome c. n = 3
independent experiments.
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Fig. 4. CAS degradation in lapatinib-resistant cells
(A) BT474 and rBT474 (left) cultured in the absence of lapatinibfor1weekwere treated with
lapatinib for the indicated times and immunoblotted for CAS and actin (top). Densitometric
analysis of the abundance of CAS normalized to that of actin from four independent
experiments (means ± SEM) is shown (bottom). CAS abundance at time 0 in BT474 cells
was set at 100%. (B) rBT474 cells maintained in the presence of lapatinib were harvested at
various time points after removal of lapatinib and immunoblotted for CAS and actin (top).
Densitometric analysis of the abundance of CAS normalized to that of actin from four
independent experiments (means ± SEM) is shown (bottom). CAS abundance at time 0 was
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set at 100%. (C) BT474 and rBT474 cells expressing FLAG-tagged CAS were treatedwith
cycloheximide(CHX)andlapatinibfortheindicated times and immunoblotted for FLAG and
actin (top). Densitometric analysis of the abundance of FLAG-CAS normalized to that of
actin from four independent experiments (means ± SEM) is shown (bottom). FLAG-CAS
abundance at time 0 in each cell line was set at 100%. (D) BT474 and rBT474 expressing
FLAG-CAS and HA-Ub were treated with lapatinib and z-VAD and harvested after MG132
treatment. FLAG-CAS immunoprecipitates were immunoblotted for HA to analyze
ubiquitylation of CAS. n = 2 independent experiments. (E) H1299 cells were transfected
with empty vector, FLAG-CAS WT, or FLAG-CASW127A. Immunoprecipitates of the
FLAG-tagged proteins were immunoblotted for MDM2. Densitometric analysis of the
abundance of immunoprecipitated MDM2 normalized to that of FLAG-CAS WT or FLAG-
CASW127A from four independent experiments is shown (means ± SEM). The amount of
MDM2 bound to FLAG-CAS WT was set at 100% (*P < 0.05 by paired, two-tailed t test).
(F) BT474 and rBT474 cells expressing FLAG-CAS were treated with lapatinib and z-VAD
and harvested after MG132 treatment. FLAG-CAS immunoprecipitates were immunoblotted
to detect association of endogenous MDM2. Densitometric analysis of the abundance of
immunoprecipitated MDM2 normalized to that of immunoprecipitated FLAG-CAS is shown
(means ± SEM; n = 4 independent experiments). The immunoprecipitated MDM2 in BT474
cells without any treatments was set at 100% (*P < 0.05 by paired, two-tailed t test). (G)
H1299 cells expressing empty vector, FLAG-CASW127A, or FLAG-CAS WT were treated
with MG132. Ubiquitylation of CAS was analyzed after immunoprecipitation. n = 2
independent experiments. (H) H1299 cells expressing MDM2 (WT, C/A mutant, or empty
vector), FLAG-CAS (WT or F123A mutant), and GFP (transfection control) were
immunoblotted for FLAG, MDM2, GFP, and actin. n = 3 independent experiments.
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Fig. 5. MDM2-mediated ubiquitylation and degradation of HUWE1 in lapatinib-resistant cells
(A) Cells treated with lapatinib for various times were immunoblotted for HUWE1, MDM2,
and actin. See fig. S17 for the densitometric analysis. n = 3 independent experiments except
MDM2 in SUM190/rSUM190 cells (n = 5) and HUWE1 in AU565/rAU565 cells (n = 4).
(B) BT474 and rBT474 cells expressing HA-tagged HUWE1 were treated with
cycloheximide and lapatinib for various times and immunoblotted for HA and actin.
Densitometric analysis of the abundance of HA-HUWE1 normalized to that of actin is
shown (means ± SEM; n = 4 independent experiments). HA-HUWE1 abundance at time 0
was set at 100%. (C) H1299 cells were transfected with empty vector, HA-HUWE1W1202A,
or HA-HUWE1WT.Immunoprecipitates of HA-tagged proteins were immunoblotted to
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detect the association of MDM2 (left). Densitometric analysis of the abundance of
immunoprecipitated MDM2 normalized to that of immunoprecipitated HA-HUWE1 is
shown (means ± SEM; n=4 independentexperiments). The amount of MDM2 that
precipitated with HA-HUWE1 WT was set at 100% (*P < 0.05 by paired, two-tailed t test).
(D) Fluorescence polarization binding assays were performed with recombinant human
MDM2 protein and the indicated peptides. IC50 ± SD, Ki ± SD, and a representative binding
curve from threeindependentexperiments are shown. (E) BT474 cells expressing increasing
amounts of MDM2 were immunoblotted for HUWE1 and actin. n = 2 independent
experiments. (F) SUM190 cells transfected with scrambled or MDM2-specific siRNA were
immunoblotted for HUWE1, MDM2, and actin. n = 3 independent experiments. (G)
Ubiquitylation of HUWE1 was reconstituted in vitro by incubating recombinant
HUWE11-2472 protein with E1, UbcH5 (E2), ubiquitin (Ub), and recombinant MDM2
protein in reaction buffer. The reactions were immunoblotted for HUWE1. n = 4
independent experiments. (H) rBT474 cells were initially transfected with scrambled or
MDM2-specific siRNA, then with HA-tagged HUWE1 (WT). Cells were treated with
lapatinib. After 24 hours, cycloheximide was added to the culture medium for various times,
and cells were immunoblotted for HA and actin. Densitometric analysis of the abundance of
HA-HUWE1 normalized to that of actin at each time point is shown (means ± SEM; n = 3
independent experiments). HA-HUWE1 abundance at time 0 was set at 100%.
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Fig. 6. MDM2 inhibition can reverse lapatinib resistance
(A) rBT474 cells transfected with scrambled or MDM2-specific siRNA were treated with
lapatinib and subjected to annexin V staining. The percentage of annexin V-positive cells
was analyzed by FACS. Results are mean percentages ± SEM and analyzed by paired, two-
tailed t test (*P < 0.05, n = 4 independent experiments). (B) rBT474 cells stably expressing
control or MDM2-specific shRNA (#1 or #2) were injected into the mam-mary fat pad of
female nude mice. The oral administration of lapatinib began when the average tumor
volume surpassed 300mm3.Resultsaremean percentages ± SEM. The statistical difference in
tumor volume was analyzed by one-way analysis of variance (ANOVA) (P < 0.001)
followed by pairwise comparisons using the Bonferroni correction for multiple comparisons.
*P < 0.05 between control and shMDM2 #1, and between control and shMDM2 #2 when the
mice were treated with lapatinib. n values in the figure indicate the number of mice. (C)
H1299 cells transfected with HA-HUWE1 (C/S) were treated with Nutlin-3a. HA-HUWE1
(C/S) immunoprecipitates were immunoblotted for MDM2 (left). Densitometric analysis of
the abundance of immunoprecipitated MDM2 normalized to that of immunoprecipitated
HA-HUWE1 (C/S) is shown (means ± SEM; n = 4 independent experiments). The amount
of MDM2 that precipitated with HUWE1 in the absence of Nutlin-3a was set at 100% (*P <
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0.05 by paired, two-tailed t test). (D) rSKBR3 cells were cultured in the presence or absence
of lapatinib for a week, and then treated with Nutlin-3a and z-VAD for the indicated times.
Cells were immunoblotted for HUWE1, CAS, MDM2, PP5, Mcl-1, and actin. See fig. S17
for the densitometric analysis. n = 6 independent experiments. (E) BT474 and rBT474 cells
were injected into the mammary fad pad of each mouse. When tumors developed to a size of
200 mm3, the mice were randomly assigned to receive vehicle, lapatinib, Nutlin-3, or
lapatinib and Nutlin-3. Results are mean percentages ± SEM. The statistical difference in
tumor volume was analyzed by one-way ANOVA (P = 0.003 and P < 0.001 for BT474 and
rBT474 xenografts. respectively) followed by pairwise comparisons using the Bonferroni
correction for multiple comparisons. (Top) *P < 0.05 between control and lapatinib and
between control and lapatinib + Nutlin-3, whereas the difference was not significant
between control and Nutlin-3 in BT474 xenografts. (Bottom) *P < 0.05 between control and
lapatinib + Nutlin-3, whereas there was no significant difference between control and
Nutlin-3, and between control and lapatinib in rBT474 xenografts. n values in the figure
indicate the number of mice. (F) rAU565 cells stably expressing control or p53-specific
shRNA were treated with DMSO (dimethyl sulfoxide) or Nutlin-3a in the presence or
absence of lapatinib. The percentage of apoptotic cell death was measured by FACS analysis
with annexin V. Results are mean percentages ± SEM of annexin V-positive cells (*P < 0.05
by paired, two-tailed t test). n = 4 independent experiments. (G) Model for coordinate
control of multiple apoptotic regulators by the MDM2 and HUWE1. In sensitive cells,
lapatinib promotes degradation of MDM2, which leads to decreases in the degradation of
CAS. Loss of MDM2 also results in increased abundance of HUWE1, which results in more
PP5 and Mcl-1 degradation. In lapatinib-resistant cells, MDM2 promotes decreased CAS
abundance, decreased HUWE1 abundance, and, consequently, increased abundance of PP5
and Mcl-1. In aggregate, these changes render the cells resistant to lapatinib-induced
apoptosis.
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